Scarica l'app Stockscreener
0.7008
3.04%
0.0207
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.6801
Aprire:
$0.68
Volume 24 ore:
393.73K
Relative Volume:
0.51
Capitalizzazione di mercato:
$38.35M
Reddito:
-
Utile/perdita netta:
$-40.56M
Rapporto P/E:
-0.599
EPS:
-1.17
Flusso di cassa netto:
$-35.28M
1 W Prestazione:
-1.99%
1M Prestazione:
-27.02%
6M Prestazione:
-39.59%
1 anno Prestazione:
-53.28%
Intervallo 1D:
$0.68
$0.7495
Intervallo di 1 settimana:
$0.666
$0.7519
Portata 52W:
$0.666
$2.20
Pds Biotechnology Corporation Stock (PDSB) Company Profile
Nome
Pds Biotechnology Corporation
Settore
Industria
Telefono
800-208-3343
Indirizzo
303A COLLEGE ROAD EAST, PRINCETON
Compare PDSB vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PDSB
Pds Biotechnology Corporation
|
0.7008 | 37.22M | 0 | -40.56M | -35.28M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Pds Biotechnology Corporation Stock (PDSB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-11-01 | Iniziato | B. Riley Securities | Buy |
| 2021-06-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-11-10 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-05-27 | Iniziato | Alliance Global Partners | Buy |
| 2020-03-09 | Iniziato | Noble Capital Markets | Outperform |
| 2019-10-24 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Pds Biotechnology Corporation Borsa (PDSB) Ultime notizie
Can PDS Biotechnology Corporation stock outperform in a bear marketWeekly Trade Review & Daily Volume Surge Signals - mfd.ru
PDS Biotech’s Big Bet Rides On Two Trial Readouts - Finimize
Growth Review: Can PDS Biotechnology Corporation stock outperform in a bear marketJuly 2025 Update & Weekly High Momentum Picks - baoquankhu1.vn
PDS Biotechnology: Regulatory Agreement Paves Way for Accelerated Cancer Therapy Review - AD HOC NEWS
PDS Biotech reports 9.6-month progression-free survival in prostate cancer study By Investing.com - Investing.com South Africa
PDS Biotech reports 9.6-month progression-free survival in prostate cancer study - Investing.com Nigeria
PDS Biotechnology Corporation Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI - marketscreener.com
PDS Biotechnology Corporation Reports 9.6 Months Median Progression-Free Survival from NCI-Led Study of PDS01ADC in Advanced Prostate Cancer - Quiver Quantitative
PDS Biotech Announces Presentation of Preliminary Results - GlobeNewswire
PDS Biotech secures patent for cancer immunotherapy PDS0101 By Investing.com - Investing.com Nigeria
PDS Biotechnology Secures Key Patent Strengthening PDS0101 Protection - TipRanks
PDS Biotech secures patent for cancer immunotherapy PDS0101 - Investing.com
PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101 - The Manila Times
Aug Macro: Can PDS Biotechnology Corporation stock outperform in a bear market2025 Key Highlights & Fast Entry High Yield Tips - baoquankhu1.vn
Earnings Miss: Can STRW maintain sales growthMarket Risk Analysis & Daily Volume Surge Trade Alerts - baoquankhu1.vn
Growth Value: Is PDS Biotechnology Corporation trading at a discount - baoquankhu1.vn
Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 - Benzinga
PDS Biotechnology Corporation (PDSB) stock: surges as FDA protocol amendment aims for accelerated approval - parameter.io
PDS Biotech stock soars after FDA meeting provides accelerated approval path By Investing.com - Investing.com South Africa
PDS Biotech stock soars after FDA meeting provides accelerated approval path - Investing.com Nigeria
PDS Biotech Announces FDA Alignment on Use of Progression Free Survival as Primary Endpoint - marketscreener.com
PDS Biotech submits amended protocol for phase 3 cancer trial By Investing.com - Investing.com India
PDS Biotech Files Amended Protocol for Phase 3 VERSATILE-003 Trial to Seek Accelerated Approval of PDS0101 - Quiver Quantitative
Cancer trial tweak could get a new head and neck treatment to patients faster - Stock Titan
How institutional buying supports PDS Biotechnology Corporation stockJuly 2025 Fed Impact & Free Reliable Trade Execution Plans - Улправда
Is PDS Biotechnology Corporation stock resilient to inflation2025 Earnings Impact & AI Forecasted Entry/Exit Points - ulpravda.ru
Does PDS Biotechnology Corporation stock trade at a discount to peersM&A Rumor & Verified Short-Term Trading Plans - Улправда
PDS Biotechnology (NASDAQ:PDSB) Trading 5% Higher – Here’s Why - Defense World
Aug Sentiment: How PDS Biotechnology Corporation stock trades during market volatility2025 Pullback Review & Entry and Exit Point Strategies - Улправда
How interest rate cuts could boost PDS Biotechnology Corporation stockSell Signal & Reliable Entry Point Alerts - Улправда
Guidance Update: Does PDS Biotechnology Corporation stock trade at a discount to peersMarket Volume Report & Verified Momentum Watchlists - Улправда
Can PDS Biotechnology Corporation stock sustain institutional interest2025 Pullback Review & Weekly Chart Analysis and Trade Guides - DonanımHaber
Will PDS Biotechnology Corporation stock continue upward momentum2025 Institutional Moves & Daily Market Momentum Tracking - bolumsonucanavari.com
How PDS Biotechnology Corporation stock performs after earningsJuly 2025 Update & Capital Efficiency Focused Ideas - DonanımHaber
Aug Spikes: How supply chain issues affect PDS Biotechnology Corporation stockWeekly Market Outlook & Real-Time Volume Trigger Notifications - moha.gov.vn
PDS Biotechnology (NASDAQ:PDSB) Shares Down 1.9% – Here’s What Happened - Defense World
Stocks of PDS Biotechnology Corporation (PDSB) are poised to climb above their peers - setenews.com
PDS Biotech secures new patent for cancer immunotherapy in Japan By Investing.com - Investing.com Australia
PDS Biotechnology Secures New Patent for PDS0101 - TipRanks
PDS Biotech secures new patent for cancer immunotherapy in Japan - Investing.com
PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan - The Manila Times
PDS Biotechnology (PDSB) Upgraded to Buy: Here's Why - sharewise.com
EPS Watch: How interest rate cuts could boost PDS Biotechnology Corporation stockTrade Risk Report & Precise Buy Zone Tips - moha.gov.vn
How supply chain issues affect PDS Biotechnology Corporation stock2025 Macro Impact & AI Powered Market Trend Analysis - Newser
A better buy-in window may exist right now for PDS Biotechnology Corporation (PDSB) - setenews.com
Is PDS Biotechnology Corporation stock ready for breakoutOptions Play & Real-Time Volume Spike Alerts - Newser
Pds Biotechnology Corporation Azioni (PDSB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):